NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received $60 million in funding from Eli Lilly Investment Consulting Co., Ltd., Zhejiang Runtu Co., Ltd., SDIC Capital Co.,Ltd
July 05, 2022
Share
NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received $60,000,000 in a round of funding on July 6, 2022. The transaction included participation from Zhejiang Runtu Co., Ltd., existing investors SDIC Capital Co.,Ltd, and Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
SDIC Capital Co., Ltd, formerly SDIC Essence (Holdings) Co., Ltd, is a China-based company principally engaged in the securities business. The Company operates through five segments. The Brokerage segment manily includes brokerage business of securities and futures and the agent sales of financial products. Entrusted Asset Management segment mainly includes the pooled asset management, directional asset management and specific asset management. Proprietary Business segment mainly invests the Companyâs funds in equity securities, fixed income securities and derivatives and is involved in the market making business in the new over-the-counter (OTC) market. Investment Banking segment includes stock financing, bond financing, mergers and acquisitions and financial advisory services. Margin Trading segment includes margin trading, stock pledged repo and agreed-to-repurchase securities.
NovoCodex Biopharmaceuticals Co., Ltd. announced that it has received $60 million in funding from Eli Lilly Investment Consulting Co., Ltd., Zhejiang Runtu Co., Ltd., SDIC Capital Co.,Ltd